idiopathic dizziness; this case was received via regulatory authority (reference number: gb-mhra-adr 26652354) on 27-feb-2022 and was forwarded to moderna on 27-feb-2022. this regulatory authority case was reported by a consumer and describes the occurrence of dizziness (idiopathic dizziness) in a female patient of an unknown age who received mrna-1273 (moderna covid-19 vaccine) (batch no. 000050a) for an unknown indication. concomitant products included candesartan and furosemide for hypertension, covid-19 vaccine nrvv ad (chadox1 ncov-19) (covid-19 vaccine astrazeneca) and elasomeran (covid-19 vaccine moderna) for vaccination, influenza vaccine (influenza virus) for an unknown indication. on 20-feb-2022, the patient received third dose of mrna-1273 (moderna covid-19 vaccine) (unknown route) 1 dosage form. on 23-feb-2022, after starting mrna-1273 (moderna covid-19 vaccine), the patient experienced dizziness (idiopathic dizziness) (seriousness criterion medically significant). at the time of the report, dizziness (idiopathic dizziness) had not resolved. the action taken with mrna-1273 (moderna covid-19 vaccine) (unknown) was unknown. no treatment medication reported. patient had not symptoms associated with covid-19 and did not have an covid-19 test. patient had not tested positive for covid-19 since having the vaccine. patient was not enrolled in clinical trial. this report was not related to possible inflammation of the heart (myocarditis or pericarditis). company comment: this regulatory authority case concerns a female patient of unknown age, with history of hypertension, who experienced the serious (medically significant) unexpected event of dizziness 3 days after receiving a dose of mrna-1273. patient previous vaccination schedule included one dose of chadox 1 ncov-19 vaccine and a dose of mrna-1273. patient's history of hypertension treated with candesartan and furosemide remains as a confounder. the benefit-risk relationship of mrna-1273 is not affected by this report.; sender's comments: this regulatory authority case concerns a female patient of unknown age, with history of hypertension, who experienced the serious (medically significant) unexpected event of dizziness 3 days after receiving a dose of mrna-1273. patient previous vaccination schedule included one dose of chadox 1 ncov-19 vaccine and a dose of mrna-1273. patient's history of hypertension treated with candesartan and furosemide remains as a confounder. the benefit-risk relationship of mrna-1273 is not affected by this report